Lab-made nanoparticles made with Salvia hispanica were tested and showed antibacterial effects, anti-virulence activity, and selective cancer cell killing.
The study describes a plant-based, “green” synthesis method for nickel-doped zinc oxide (Ni–ZnO) nanoparticles. Chemical analysis of the Salvia hispanica extract identified phenolic and flavonoid compounds, which the authors say helped drive nanoparticle formation and keep the particles stable. Multiple lab techniques indicated crystalline, mostly spherical nanoparticles of about 72 nm, with nickel incorporated into the zinc oxide structure.
Biological testing found that the Ni–ZnO nanoparticles showed selective cytotoxicity against HNO97 cancer cells, while sparing normal HOEC cells more at the same conditions. The nanoparticles also promoted apoptosis and arrested cells in the G2/M phase. On the infection side, the work reports bactericidal activity against Staphylococcus aureus, reduced biofilm formation, and downregulation of virulence genes including exoS, toxA, fimH, and papC.
Bacteria and cancer lab effects
Using Salvia hispanica extract, the researchers synthesized crystalline Ni–ZnO nanoparticles with an average size of about 72 nm and reported nickel ions integrated into the ZnO crystal framework. In cell tests, the nanoparticles showed selective cytotoxicity with IC₅₀ values of 139.9 µg/mL in HNO97 cancer cells and 284.6 µg/mL in normal HOECs. Flow cytometry indicated apoptosis (50.0% early and 22.5% late) and strong cell cycle arrest at the G2/M phase (70.6%).
For bacteria, the nanoparticles showed potent antibacterial interest against Staphylococcus aureus, with bactericidal effects supported by MIC and MBC analyses. They also inhibited biofilm formation by up to ~65% and reduced virulence gene expression, including exoS, toxA, fimH, and papC. In antioxidant assays, they showed moderate radical-quenching with IC₅₀ values of 359 µg/mL (DPPH) and 434 µg/mL (ABTS), lower efficiency than ascorbic acid.
Lab tests, no in vivo results
This is laboratory evidence based on nanoparticle characterization (UV–Vis, FTIR, XRD, TEM, SEM, EDX, DLS, and zeta potential) and biological testing in cell systems and antibacterial assays. The abstract does not describe animal studies, clinical testing, or details about the test conditions (such as exposure times and concentrations for each assay), so the findings’ relevance to real-world treatments remains uncertain. The antibacterial “broad-spectrum” claim is not fully specified in the abstract beyond the highlighted results for Staphylococcus aureus.
